Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Nov 7, 2023--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of five studies (one oral and four posters) at the annual American College of Rheumatology Convergence 2023 taking ...

